HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.
Apr 13, 2023
HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting
Apr 11, 2023
HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-medicines, completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023 in Taipei, Taiwan with world-renowned professors and few Board of Director (BOD) members.
Apr 17, 2023
HANCHORBIO ANNOUNCES US IND CLEARANCE FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.